price up icon0.77%   +0.36
after-market  After Hours:  47.02 
Simulations Plus Inc. stock is currently priced at $47.02, with a 24-hour trading volume of 101.85K. It has seen a +0.77% increased in the last 24 hours and a -7.71% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $47.15 pivot point. If it approaches the $46.02 support level, significant changes may occur.
Previous Close:
24h Volume:
Market Cap:
Net Income/Loss:
P/E Ratio:
Net Cash Flow:
1W Performance:
1M Performance:
6M Performance:
1Y Performance:
1D Range:
52W Range:

Simulations Plus Inc. Stock (SLP) Company Profile

Simulations Plus Inc.
42505 Tenth Street West, Lancaster, CA
Next Earnings Date
Latest SEC Filings
SLP's Discussions on Twitter

Simulations Plus Inc. Stock (SLP) Upgrades & Downgrades

Date Action Analyst Rating Change
May-09-23 Initiated BTIG Research Buy
Oct-26-21 Upgrade Craig Hallum Hold → Buy
Jan-12-21 Downgrade Craig Hallum Buy → Hold
Oct-16-20 Initiated Raymond James Outperform
Sep-08-20 Initiated Oppenheimer Outperform
Jan-06-20 Initiated Craig Hallum Buy
View All

Simulations Plus Inc. Stock (SLP) Financials Data

Simulations Plus Inc. (SLP) Revenue 2024

SLP reported a revenue (TTM) of $64.67 million for the quarter ending February 29, 2024, a +18.86% rise year-over-year.

Simulations Plus Inc. (SLP) Net Income 2024

SLP net income (TTM) was $10.52 million for the quarter ending February 29, 2024, a +0.47% increase year-over-year.

Simulations Plus Inc. (SLP) Cash Flow 2024

SLP recorded a free cash flow (TTM) of $12.76 million for the quarter ending February 29, 2024, a -29.71% decrease year-over-year.

Simulations Plus Inc. (SLP) Earnings per Share 2024

SLP earnings per share (TTM) was $0.53 for the quarter ending February 29, 2024, a +6.00% growth year-over-year.
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organizes, processes, maintains, and communicates the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.
health_information_services EVH
price up icon 0.00%
price down icon 1.00%
price down icon 1.41%
health_information_services WAY
price down icon 1.73%
price down icon 5.96%
health_information_services RCM
price down icon 0.48%
Cap:     |  Volume (24h):